Rare in Common: Building Rare Disease Communities
Saturday, March 12
12:30PM - 1:30PM
110 E 2nd St
Living with a rare disease is dangerous, depressing, and isolating. Digital innovation provides an incredible opportunity to unite isolated, extremely ill people together for a common cause—discovering fellowship, engendering hope, and taking action to pursue their health as individuals and as a collective.
Our session will explore the potential and impact of these digital communities with rare diseases in common from the point of view of multiple stakeholders: the people facing rare diseases themselves, companies dedicated to developing medicines for them, and thought leaders in rare disease communications.
Our video shows how rare disease patients are connecting & their strength
Co-Founder & Pres
Andra Stratton is a patient with familial partial lipodystrophy and an advocate for the global lipodystrophy community. She is a founding member and current President of Lipodystrophy United. Over...Show the rest
Andra Stratton is a patient with familial partial lipodystrophy and an advocate for the global lipodystrophy community. She is a founding member and current President of Lipodystrophy United. Over the last four years, she has led the efforts to increase awareness and support among patients for all types of lipodystrophy around the world. She has worked closely with lipodystrophy stakeholders and has been the patient voice in meetings and conferences in the United States and Europe. Additionally, Ms Stratton is a governing board member for Lipodystrophy Connect, the patient registry. Andra received her Masters of Arts in Industrial Organizational Psychology and worked as a consultant for two decades in human resource and organizational policies and procedures. Her professional background, in addition to her personal experiences as a patient, has allowed her to represent the patient community with great success.Hide the rest
Head of U S Mktg
Daniel Yip, WG’08 is currently the Head of U.S. Marketing at Intercept Pharmaceuticals, a biopharmaceutical company focused on developing innovative therapies for non-viral chronic liver diseases. ...Show the rest
Daniel Yip, WG’08 is currently the Head of U.S. Marketing at Intercept Pharmaceuticals, a biopharmaceutical company focused on developing innovative therapies for non-viral chronic liver diseases. He currently leads the US marketing efforts for the potential commercial launch of a drug for a rare liver disorder called primary biliary cirrhosis. He was previously Director of Business Operations at Amicus Therapeutics, where his responsibilities included commercial and business development, strategic planning, and program management. Prior to Amicus, Daniel was a key member of the Rituxan brand team at Genentech where he launched the product for the treatment of rheumatoid arthritis. Before Genentech, Daniel spent several years in sales at GlaxoSmithkline where he launched Advair Diskus for asthma. Daniel received his M.B.A. from Wharton with a concentration in Healthcare Management. He received his B.A. in Molecular and Cell Biology and M.P.H. in Health Policy and Management from the University of California, Berkeley. He currently lives and works in New York City.Hide the rest
Chief Strategy Officer
Innovatively-driven business strategist, with more than 20 years of demonstrated expertise in managing multi-channel marketing and client services for organizations ranging from startups to global,...Show the rest
Innovatively-driven business strategist, with more than 20 years of demonstrated expertise in managing multi-channel marketing and client services for organizations ranging from startups to global, multi-billion dollar enterprises. Exceptional communicator and negotiator, with successful record of leading talented teams and securing key clients. Skillfully develop and implement unique marketing strategies and interactive campaigns that build brand awareness and deliver multi-million dollar profitability. Broad-based experience spans pharmaceutical, healthcare advertising, digital, multi-channel, branding, nutritional / dietary, and consumer packaged goods companies.
Chief Strategy Officer @ Cambridge BioMarketing
VP, Strategy Planning & Analytics @ Epsilon
SVP, Account Group Supervisor @ Saatchi & Saatchi Healthcare
VP, Director of Client Services @ 22clicks
Lisa brings a unique blend of experience in developing patient communities for rare disease populations and executing integrated marketing programs. Her keen sense of patient/user needs and commercial imperatives adds both practicality and innovation to the conversation. Lisa can serve as the moderator for the session given her breadth and depth of experience.
Dir of Medical Strategy
Sam has more than a decade of drug development and commercialization experience in the pharmaceutical, academic, and biotech worlds. Prior to joining Cambridge BioMarketing he worked at the Publici...Show the rest
Sam has more than a decade of drug development and commercialization experience in the pharmaceutical, academic, and biotech worlds. Prior to joining Cambridge BioMarketing he worked at the Publicis Groupe, where he led scientific strategy on multiple antiviral products as well as groundbreaking investigational oncology therapies. While in academic drug discovery, Sam was part of a research team that developed and successfully licensed 3 oncology agents, including a first-in-class targeted oncology therapy currently in phase I clinical trials. Sam has helped develop the scientific and clinical strategies and narratives for at least a dozen rare diseases and orphan products. His expertise is complemented by the clinical department of PhDs and MDs that he and CB have cultivated. In addition to his work at CB Sam is a member of a data monitoring committee for the NCI Community Clinical Oncology Program and has served as President of a chapter of the American Medical Writers Association.
Director of Medical Strategy @ Cambridge BioMarketing August 2012 – Present Data Monitoring Committee Member @ National Cancer Institute Community Clinical Oncology Program May 2008 – Present Clinical Science Director @ Cambridge BioMarketing January 2011 – August 2012 Scientific Director @ Discovery Chicago October 2010 – January 2011
PRIOR SPEAKING EXPERIENCE
Regular speaker at medical institutions to help clinicians transition into commercial roles. Also a facilitator at advisory board meetings with both healthcare professionals and patient groups.
Sam brings an unique perspective of clinical understanding to the conversations. His years in experience with orphan and ultra-orphan disease give him the ability to speak from not only a medical standpoint but also from the practicing physician's point of view